Navigation Links
AEterna Zentaris To Present First In Vitro Data for PI3K Inhibitors,and In Vivo Results for a GHRH Antagonist at the AACR Annual,Meeting in Los Angeles

QUEBEC CITY, April 13, 2007 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. , a global, pure play biopharmaceutical company focused on endocrine therapy and oncology, today announced that it will present two abstracts outlining first in vitro data on its PI3K inhibitors as well as in vivo data on its GHRH antagonist, JMR-132, which both may potentially provide new therapeutic approaches for the treatment of cancer. These abstracts will be presented at the American Association for Cancer Research (AACR) Annual Meeting, to be held April 14-18 at the Los Angeles Convention Center in Los Angeles, California.

    Selected abstracts for poster sessions in the Exhibit Hall:

    Monday, April 16, 8:00 a.m. - 12:00 p.m. (PT)

        - Abstract #2379 "New Generation of Anilino-Substituted

          Pyridopyrazine-Urea Derivatives Show Highly Selective PI3K-

          Inhibition". Irene Seipelt, Eckhard Claus, Tilman Schuster,

          Emmanuel Polymeropoulos, Michael Teifel, Eckhard Gunther.

          The abstract reviews, for the first time, results of a preclinical

          development program on a new generation of pyridopyrazine

          derivatives which clearly indicate that these drug candidates

          selectively inhibit PI3K and could be valuable for the treatment of


    Tuesday, April 17, 8:00 a.m. - 12:00 p.m. (PT)

        - Abstract #3568 "GHRH-Antagonist in Combination with Docetaxel

          Chemotherapy induces regression of MX-1 human experimental breast

          cancers". Joerg B. Engel, Andrew V. Schally, Jozseph Varga, Gabor

          Halmos, Stefan Buchholz.

          The abstract reviews results which demonstrate that GHRH

          antagonist, JMR-132, inhibits doxorubicin resistant in MX-1 human

          breast cancers and induces growth arrest or total regression when

          combined with docetaxel chemotherapy. Consequently, JMR-132 could

          provide a new therapeutic approach for t
he treatment of early and

          metastatic breast cancer.

Copies of these abstracts are currently available and can be viewed on-line through the AACR 2007 Meeting website at:

About AEterna Zentaris Inc.

AEterna Zentaris Inc. is a global, pure play biopharmaceutical company focused on endocrine therapy and oncology with proven expertise in drug discovery, development and commercialization.

    News releases and additional information are available at

    Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the U.S. Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements preceded by, followed by, or that include the words "believes", "anticipates", "intends", "plans", "expects", "estimates", "will," "may", "should", "approximately", and the negative or other variations of those terms or comparable terminology, are forward-looking statements. Such statements reflect management's current views, intentions, strategies and plans and are based on certain assumptions.

Forward-looking statements involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the ability of AEterna Zentaris to implement its business strategies, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of AEterna Zentaris to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. The Company does not undertake to update these forward-looking statements.

CONTACT: Jenene Thomas, Senior Director, Investor Relations & CorporateCommunications, (418) 655-6420, ; PaulBurroughs, Media Relations, (418) 652-8525 ext. 406,

Ticker Symbol: (Toronto:AEZ.),(NASDAQ-NMS:AEZS)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


Related medicine technology :

1. AEterna Zentaris Partner Keryx Presents Phase 1 and Phase 2 Results for Anti-Cancer Compound Perifosine at ASCO Meeting
2. AEterna Zentaris Partner, Spectrum, Discloses Detailed Phase 2 Data for Ozarelix, in BPH at Annual AUA Meeting
3. AEterna Zentaris Discloses In Vivo Data for its GHRH Antagonist JMR-132 at the AACR Annual Meeting in Los Angeles
4. AEterna Zentaris Discloses First In Vitro Data for its PI3K Inhibitors at the AACR Annual Meeting in Los Angeles
5. AEterna Zentaris Reports Positive Results with Cetrorelix in BPH for Japanese Phase 2a Trial
6. terna Zentaris Discloses First In Vitro Data for its PI3K Inhibitors at the AACR Annual Meeting in Los Angeles
7. The Past, Present and Future of HLA Typing
8. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
9. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
11. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
Post Your Comments:
(Date:10/12/2015)... A new computer program that analyzes functional brain MRIs ... develop effective language skills within two years of cochlear ... Brain and Behavior . ... 12 online edition, researchers at Cincinnati Children,s Hospital Medical ... of the brain respond to auditory stimulus tests that ...
(Date:10/12/2015)... 2015  To help address the growing opioid epidemic ... Surgeons (AAOS) Board of Directors is calling for ... patient education; the tracking of opioid prescription use; research ... effective opioid abuse treatment programs. David Ring ... Safety Committee. "The new , AAOS Information Statement on ...
(Date:10/12/2015)... , Oct. 12, 2015  Today, Divurgent is honored to ... Services. As a former CIO, Paul brings 15 years of ... understand or sympathize with today,s CIOs, he is one. The ... challenges Paul has faced, and his new role with Divurgent ... technology efficiencies across an organization. ...
Breaking Medicine Technology:
(Date:10/13/2015)... ... 2015 , ... Georgia Partnership for TeleHealth (GPT), ... along with affiliate organizations, Alabama Partnership for Telehalth (ATP) and Florida Partnership for ... 2015. , Each of the three conferences share this year’s conference theme, ...
(Date:10/13/2015)... Cheyenne, Wyoming (PRWEB) , ... October 13, 2015 , ... ... at the Gold’s Gym International Conference on August 26. Berry, who owns and operates ... exemplary standards for the fastest growing Gold’s Gyms in the United States. A brand ...
(Date:10/13/2015)... ... ... With Fall weather approaching and holiday travel season upon us, is giving ... Enter to win! , How to Enter:, 1. Like on Facebook , ... Follow us on Instagram @thebeautyplace , 4. Share Facebook Contest Image With Friends ...
(Date:10/13/2015)... ... October 13, 2015 , ... Bambeco, ... furnishings and décor, today announced it closed on a $20.5 million funding round ... be used to support the Company’s continued rapid growth and expansion, broaden the ...
(Date:10/13/2015)... , ... October 13, 2015 , ... ... National Women’s show this coming October in Toronto, an exhibition featuring the newest ... to choose from, Curly Hair Solutions® couldn’t be more excited to unveil their ...
Breaking Medicine News(10 mins):